4.8 Article

Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non-ST-Segment-Elevation Acute Coronary Syndromes

期刊

CIRCULATION
卷 126, 期 1, 页码 41-49

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.111.071860

关键词

acute coronary syndrome; mortality; tachycardia, ventricular; ventricular fibrillation

资金

  1. Schering-Plough Corporation
  2. Merck Co, Inc.
  3. Boston Scientific
  4. Johnson Johnson
  5. Bayer Healthcare
  6. Janssen Pharmaceuticals, Inc
  7. Forest Laboratories
  8. Sanofi-Aventis
  9. Medtronic
  10. Biotronik
  11. Merck Co, Inc
  12. Schering-Plough
  13. Bristol Myers Squibb
  14. Centocor
  15. Cordis
  16. Eli-Lilly
  17. Federation Franaise de Cardiologie
  18. Fondation de France
  19. Guerbet Medical
  20. INSERM
  21. ITC Edison
  22. Pfizer
  23. Sanofi-Aventis Group
  24. Societe Franaise de Cardiologie
  25. Accumetrics
  26. AstraZeneca
  27. Bayer
  28. Boehringer-Ingelheim
  29. Bristol-Myers Squibb
  30. Daichi-Sankyo
  31. Eisai
  32. Menarini
  33. MSD
  34. Novartis
  35. Portola
  36. Merck
  37. Roche
  38. Daiichi-Sankyo

向作者/读者索取更多资源

Background-Ventricular arrhythmias remain a lethal complication of acute coronary syndromes (ACS). However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in contemporary non-ST-segment-elevation (NSTE) ACS populations are not well described. Methods and Results-We examined the incidence of VT/VF and subsequent survival among 9211 patients enrolled in the Early Glycoprotein IIb/IIIa Inhibition in NSTE ACS (EARLY ACS) trial. The cumulative incidence of VT/VF was 1.5% (n = 141); 0.6% (n = 55) had VT/VF <= 48 hours after enrollment, and 0.9% (n = 86) had VT/VF >48 hours after enrollment. Patients with VT/VF more frequently had prior heart failure, an ejection fraction <30%, and triple-vessel coronary artery disease. Predictors of sustained VT/VF were similar regardless of the timing of VT/VF (<= 48 versus >48 hours). Patients with VT/VF <= 48 hours after enrollment had higher 30-day mortality than those who did not have VT/VF <= 48 hours (13.0% versus 2.2%; adjusted odds ratio, 6.73; 95% confidence interval, 2.68-16.9). The increased risk of death associated with VT/VF <= 48 hours persisted at 1 year. The risk of mortality, relative to patients without VT/VF, was greater for patients with VT/VF <= 48 hours (hazard ratio, 20.70; 95% confidence interval, 15.39-27.85) than for those with earlier VT/VF (hazard ratio, 7.45; 95% confidence interval, 4.60-12.08; P = 0.0003). The frequency of arrhythmic death was higher in patients with VT/VF than in those without VT/VF (26.4% versus 6.9%). Conclusions-Sustained VT/VF is infrequent after NSTE ACS but is as likely to occur after 48 hours as within the first 48 hours. The marked increase in all-cause death among NSTE ACS patients with both early and late sustained VT/VF raises important considerations for aggressive monitoring beyond 48 hours and interventions to prevent arrhythmic death in these patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据